We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

59 hedge funds and large institutions have $3.34M invested in Oncolytics Biotech in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 3 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

467% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 3

36% more capital invested

Capital invested by funds: $2.45M → $3.34M (+$887K)

1.06% more ownership

Funds ownership: 2.79% → 3.84% (+1.1%)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

3% less funds holding

Funds holding: 61 → 59 (-2)

Holders
59
Holders Change
-2
Holders Change %
-3.28%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
17
Reduced
3
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$712K
2
Marshall Wace
Marshall Wace
United Kingdom
+$594K
3
SFP
Sandbox Financial Partners
Maryland
+$398K
4
EFG
Everhart Financial Group
Ohio
+$137K
5
DA
Doliver Advisors
Texas
+$99.5K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$396K
2
IAIM
International Assets Investment Management
Florida
-$182K
3
Goldman Sachs
Goldman Sachs
New York
-$148K
4
CCM
Connective Capital Management
California
-$131K
5
VF
Virtu Financial
New York
-$68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$23.8K -$396K -398,531 -93%
TSS
27
Two Sigma Securities
New York
$21.8K +$25.5K +25,627 New
National Bank of Canada
28
National Bank of Canada
Quebec, Canada
$20.9K – – –
HF
29
HRT Financial
New York
$19K +$11.2K +11,263 +94%
Rockefeller Capital Management
30
Rockefeller Capital Management
New York
$17.8K – – –
PAS
31
Professional Advisory Services
Florida
$17K – – –
Truist Financial
32
Truist Financial
North Carolina
$17K +$19.9K +20,000 New
Citadel Advisors
33
Citadel Advisors
Florida
$15.2K +$17.8K +17,938 New
PNC Financial Services Group
34
PNC Financial Services Group
Pennsylvania
$12.8K – – –
Creative Planning
35
Creative Planning
Kansas
$12.3K +$1.21K +1,215 +9%
AC
36
AlphaCore Capital
California
$10.6K -$9.95K -10,000 -44%
AFP
37
Ausdal Financial Partners
Iowa
$10.2K – – –
KWM
38
Kingsview Wealth Management
Oregon
$9.52K – – –
Cambridge Investment Research Advisors
39
Cambridge Investment Research Advisors
Iowa
$9K +$10.7K +10,771 New
Cerity Partners
40
Cerity Partners
New York
$8.49K – – –
CAG
41
Crestwood Advisors Group
Massachusetts
$8.49K +$9.95K +10,000 New
AF
42
Allworth Financial
California
$7.17K – – –
Osaic Holdings
43
Osaic Holdings
Arizona
$6.97K +$2.62K +2,637 +47%
Wells Fargo
44
Wells Fargo
California
$5.6K +$1.19K +1,201 +22%
Northwestern Mutual Wealth Management
45
Northwestern Mutual Wealth Management
Wisconsin
$5.43K +$6.36K +6,393 New
CMA
46
Cedar Mountain Advisors
Oregon
$4.8K – – –
AWM
47
Activest Wealth Management
Florida
$4.24K – – –
LFG
48
Larson Financial Group
Missouri
$4.24K +$4.97K +5,000 New
Jones Financial Companies
49
Jones Financial Companies
Missouri
$3.59K +$2.21K +2,225 +108%
BlackRock
50
BlackRock
New York
$2.55K – – –
1
2
3

ONCY Hedge Fund Activity: Q1 2026 in Review

59 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2026, worth a combined $3.34M — up 36% from $2.45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ONCY and 15 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 17 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $712K. The largest seller was Morgan Stanley, cutting an estimated $396K.

  • 59 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2026, down from 61 in Q4 2025.
  • Funds reported $3.34M of Oncolytics Biotech stock for Q1 2026, up 36% quarter-over-quarter.
  • 15 funds opened new Oncolytics Biotech positions in Q1 2026 and 16 closed out, a net change of -1 holder.
  • The largest Oncolytics Biotech buyer in Q1 2026 was Renaissance Technologies, an estimated $712K added.
  • The largest Oncolytics Biotech seller in Q1 2026 was Morgan Stanley, an estimated $396K sold.

Based on aggregated 13F filings for Q1 2026.